Lorlatinib - Induced pulmonary arterial hypertension

Lung Cancer. 2018 Jun:120:60-61. doi: 10.1016/j.lungcan.2018.03.023. Epub 2018 Mar 27.

Abstract

We report here the first cases, to our knowledge, of pulmonary arterial hypertension induced by lorlatinib. It s the first time that a tyrosine kinase inhibitor for lung cancer is associated with pulmonary arteriel hypertension.

Keywords: ALK rearrangement; Lorlatinib; Lung cancer; Pulmonary hypertension; Tyrosine kinase inhibitor.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aminopyridines
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / diagnosis*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Drug-Related Side Effects and Adverse Reactions / diagnosis*
  • Dyspnea
  • Female
  • Humans
  • Hypertension, Pulmonary / diagnosis*
  • Hypertension, Pulmonary / etiology
  • Lactams
  • Lactams, Macrocyclic / adverse effects*
  • Lactams, Macrocyclic / therapeutic use
  • Lung Neoplasms / diagnosis*
  • Lung Neoplasms / drug therapy
  • Male
  • Middle Aged
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use
  • Pyrazoles
  • Vascular Resistance / drug effects
  • Walk Test
  • Withholding Treatment

Substances

  • Aminopyridines
  • Antineoplastic Agents
  • Lactams
  • Lactams, Macrocyclic
  • Protein Kinase Inhibitors
  • Pyrazoles
  • lorlatinib